January 25, 2018 / 3:05 PM / in 23 minutes BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority Reuters Staff 1 Min Read 
Jan 25 (Reuters) - Celgene Corp: 
* CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY 
* CELGENE CEO SAYS POSITIONED TO LAUNCH TWO CAR-T THERAPIES IN BLOOD CANCERS IN NEXT 3 YEARS 
* CELGENE SEES $1 BILLION SALES POTENTIAL FOR FEDRATINIB IN MYELOFIBROSIS, MID-2018 REGULATORY SUBMISSION Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)